FIG 4.

(A) OS, (B) EFS, (C) DOR, and (D) DBA outcomes stratified by disease burden. OS and EFS estimates in all infused patients with measurable disease burden. DOR and DBA estimates in patients who achieved morphologic remisson. (E) Disease burden stratification and day 28 CR rate. BM, bone marrow; CR, complete response; DBA, duration of B-cell aplasia; DOR, duration of remission; EFS, event-free survival; EM, extramedullary; HB, high-disease burden; LB, low-disease burden; MRD, minimal residual disease; OS, overall survival; UD, undetectable disease.